This week, we review data on the short-term safety of the COVID-19 vaccine in patients with cancer receiving immunotherapy. We’ll also discuss a study of the monoclonal antibody tislelizumab plus chemotherapy as first-line treatment for patients with advanced squamous non–small cell lung cancer.

Coverage of stories discussed this week on ascopost.com:

Short-Term Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients Receiving Immunotherapy

First-Line Tislelizumab Plus Chemotherapy vs Chemotherapy Alone in Advanced Squamous NSCLC

To listen to more podcasts from ASCO, visit asco.org/podcasts.